Korro Bio (KRRO) vs Protara Therapeutics (TARA)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
Protara Therapeutics (TARA) has outperformed Korro Bio (KRRO) over the past year, losing 47.7% versus a loss of 76.9%. Over five years, TARA leads with a -61.3% price change compared with -97.0% for KRRO. Protara Therapeutics is the larger company by market cap ($156.6 million vs $155.8 million), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | KRRO | TARA |
|---|---|---|
| Share price | $10.58 | $2.65 |
| Market cap | $155.80M | $156.60M |
| 1-day change | +0.86% | +2.32% |
| YTD return | +32.08% | -50.28% |
| 1-year return | -76.90% | -47.73% |
| 5-year return | -97.02% | -61.26% |
| EPS (TTM) | $-9.88 | $-1.36 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $55.89 | $7.82 |
| 52-week low | $5.20 | $2.51 |
| Distance from 52-week high | -81.07% | -66.11% |
| Analyst consensus | strong_buy | strong_buy |
| Avg. price target upside | +90.93% | +870.19% |
| Average volume | 148.86K | 804.10K |
| Shares outstanding | 14.73M | 59.10M |
| Employees | 57 | 46 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Biological Products (No Diagnostic Substances) |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- TARA has outperformed KRRO by 29.2 percentage points over the past year.
About Korro Bio
KRRO stock →Korro Bio, Inc., a biopharmaceutical company, engages in the discovering, developing, and commercializing of genetic medicines based on editing RNA for the treatment of rare and highly prevalent diseases in the United States. The company's lead product candidate is KRRO-121 for the treatment for hyperammonemia.
Health Care · Biotechnology: Pharmaceutical Preparations · 57 employees
About Protara Therapeutics
TARA stock →Protara Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in advancing transformative therapies for the treatment of cancer and rare diseases. The company's lead program is TARA-002, an investigational cell therapy, which is in Phase II clinical trial for the treatment of non-muscle invasive bladder cancer and lymphatic malformations.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 46 employees
KRRO vs TARA FAQ
Which is bigger, Korro Bio or Protara Therapeutics?
Protara Therapeutics (TARA) is larger, with a market capitalization of $156.60M compared with $155.80M for Korro Bio (KRRO).
Which stock has performed better over the past year, KRRO or TARA?
TARA returned -47.73% over the past 12 months, compared with -76.90% for KRRO (price return, excluding dividends). Past performance does not predict future results.
Are Korro Bio and Protara Therapeutics in the same industry?
Both are in the Health Care sector, but in different industries: Biotechnology: Pharmaceutical Preparations for Korro Bio and Biotechnology: Biological Products (No Diagnostic Substances) for Protara Therapeutics.